Is Pediatrix Medical Group (MD) overvalued or fairly valued?

MarketChacha shows Pediatrix Medical Group's valuation in context — a trailing P/E of about 12.6, a forward P/E of about 11.1, a price-to-book of about 2.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Pediatrix Medical Group's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (104.04×) from reported figures — education, not a rating.

What is Pediatrix Medical Group's revenue?

Pediatrix Medical Group reported revenue of $1.9B for FY2025, with net profit of $165.4M, per official filings.

What is the share price of Pediatrix Medical Group (MD)?

Pediatrix Medical Group last traded at $27.03 (+0.6% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Pediatrix Medical Group

MD · NYSE · Healthcare · United States

Snapshot

TickerMD

ExchangeNYSE

SectorHealthcare

IndustryMedical Care Facilities

CountryUnited States

Employees4,280

HeadquartersSunrise, United States

Websitewww.pediatrix.com

Filings tracked14

About Pediatrix Medical Group

Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, maternal-fetal medicine nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. It also provides other pediatric subspecialty care, including pediatric intensivists, pediatric hospitalists, and pediatric surgeons; support services in other areas of hospitals comprising pediatric emergency room, labor and delivery area, and nursery and pediatric departments; a newborn hearing screening program. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.

Who owns it

Insiders2.0%
Institutions98.0%
Public & other0.0%

425 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.16.88%
Vanguard Portfolio Management LLC7.37%
Dimensional Fund Advisors LP5.19%
Vanguard Capital Management LLC4.46%
State Street Corporation4.35%
Victory Capital Management Inc.4.21%
Wasatch Advisors LP3.08%
Geode Capital Management, LLC2.74%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion104.04×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend-3.0% → 8.6%

Margin has expanded by about 11.7 points — the business is getting more profitable.

Return on equity19.1%

Latest ROE of 19.1% — capital is generating a healthy return.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $499.1M · EPS 0.63

Est. earnings growth +26.1%

Next fiscal year

Rev $2.0B · EPS 2.44

Est. earnings growth +3.9%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$1.9B

Net margin

8.6%

ROE

19.1%

Revenue CAGR (2y)

-2.0%

EPS (FY2025)

1.94

Net profit (FY2025)

$165.4M

Ask MarketChacha about MD

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$1.9B	$165.4M	1.94	8.6%	19.1%
FY2024	$2.0B	$-99.1M	-1.19	-4.9%	-13.0%
FY2023	$2.0B	$-60.4M	-0.73	-3.0%	-7.1%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$487.8M	$39.8M	0.49	8.2%
2026Q1	$476.2M	$29.6M	0.36	6.2%
2025Q3	$492.9M	$71.7M	0.84	14.5%
2025Q2	$468.8M	$39.3M	0.46	8.4%
2025Q1	$458.4M	$20.7M	0.24	4.5%
2024Q3	$511.2M	$19.4M	0.23	3.8%
2024Q2	$504.3M	$-153.0M	-1.84	-30.3%
2024Q1	$495.1M	$4.0M	0.05	0.8%
2023Q3	$506.6M	$21.4M	0.26	4.2%
2023Q2	$500.6M	$28.3M	0.34	5.6%
2023Q1	$491.0M	$14.2M	0.17	2.9%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC8/4/2026material
10-Q filing
SEC8/4/2026
8-K — Executive/director change, Reg FD disclosure
SEC7/24/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC7/15/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC5/7/2026material
8-K — Results of operations, Exhibits
SEC5/5/2026material
10-Q filing
SEC5/5/2026
8-K — Results of operations, Exhibits
SEC2/19/2026material
10-K filing
SEC2/19/2026

2025

8-K — Results of operations, Exhibits
SEC11/3/2025material
10-Q filing
SEC11/3/2025
8-K — Reg FD disclosure, Other events, Exhibits
SEC8/18/2025material
8-K — Results of operations, Exhibits
SEC8/5/2025material
10-Q filing
SEC8/5/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.